A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses - TradingView
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses TradingView
Lonza CHI receives NutraStrong Collagen Verified certification - nutritioninsight.com
Lonza CHI receives NutraStrong Collagen Verified certification nutritioninsight.com
Future-proofing nutraceuticals: Lonza CHI on bioavailability and sensory appeal - nutritioninsight.com
Future-proofing nutraceuticals: Lonza CHI on bioavailability and sensory appeal nutritioninsight.com
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer - Contract Pharma
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer Contract Pharma
Inside Lonza CHI’s Innovation Strategy: Future-Ready Capsules for Complex Drugs - PharmTech.com
Inside Lonza CHI’s Innovation Strategy: Future-Ready Capsules for Complex Drugs PharmTech.com
Catching up with Lonza Capsules and Health Ingredients - Nutritional Outlook
Catching up with Lonza Capsules and Health Ingredients Nutritional Outlook
CDMO Joinn Biologics snaps up China biologics plant from Lonza in push to tackle Asia-Pacific market - Fierce Pharma
CDMO Joinn Biologics snaps up China biologics plant from Lonza in push to tackle Asia-Pacific market Fierce Pharma
JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy - Pharmaceutical Technology
JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy Pharmaceutical Technology
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page